查詢結果分析
相關文獻
- Relationship between Hormone Receptor Concentration and Tumor Shrinkage in Uterine Myoma after Treatment with a GnRHa
- Uterine Myoma after Cessation of Gonadotropin-Releasing Hormone Agonist: Ultrasound and Histopathologic Findings
- 婦女最常見的子宮肌瘤
- 子宮肌瘤與肌腺瘤
- 子宮肌瘤的內科療法--GnRHa
- 子宮肌瘤的組織發生論和臨床內分泌學
- A Huge 6.2 Kilogram Uterine Myoma Coinciding with Omental Leiomyosarcoma: Case Report
- 子宮肌瘤切除臨床路徑探討
- 性腺激素釋放類似劑(GnRHa)在子宮肌瘤的應用
- Major Hemorrhage in a Patient with Multiple Submucous Leiomyomata during the Treatment of Long-Acting Gonadotropin-Releasing Hormone Agonist
頁籤選單縮合
題名 | Relationship between Hormone Receptor Concentration and Tumor Shrinkage in Uterine Myoma after Treatment with a GnRHa=良性子宮肌瘤經性腺釋放激素對抗物(GnRH agonist)治療後之荷爾蒙受器濃度和腫瘤縮小之間的關係 |
---|---|
作者 | 王鵬惠; 李文齡; 趙湘臺; 舒麗萍; 高華莉; 吳秋文; 袁九重; Wang, Peng-hui; Lee, Wen-ling; Chao, Hsiang-tai; Shu, Li-ping; Kao, Hwa-li; Wu, Chiu-wen; Yuan, Chiou-chung; |
期刊 | 中華醫學雜誌 |
出版日期 | 19990500 |
卷期 | 62:5 1999.05[民88.05] |
頁次 | 頁294-299 |
分類號 | 417.281 |
語文 | eng |
關鍵詞 | 性腺釋放激素對抗物; 荷爾蒙受器; 子宮肌瘤; Gonadotropin-releasing hormone agonist; Estrogen receptors; Progesterone receptors; Uterine myoma; |
中文摘要 | 背景:良性子宮肌瘤經性腺釋放激素對抗物(GnRH agoniot)治療後,雖然可達 到某種程度的療效,但反應卻因人而異。為了探討其原因,我們設計了以下研究。 方法:前瞻性選擇5位尚未停經且有症狀的良性子宮肌瘤病人接受性腺釋放激素對抗物 goserlin 3.6 mg皮下注射,每4週為一療程,為期16週。治療前、中、後,病人均接受超 音波檢查和荷爾蒙測試。完成上述治療後,所有病人皆接受子宮肌瘤切除術。將所切下的 標本做荷爾蒙受器(包括雌激素和黃體素受器)濃度之測試。 結果:子宮肌瘤的體積縮小,從21%到65%不等。未結合型黃體素受器的濃度與腫瘤體積 減少的百分比呈負相關,而雌激素受器的濃度與腫瘤體積的減少卻無統計上的相關性。 結論 從得到的資料推論,用性腺釋放激素對抗物治療良性子宮肌瘤,病人之間出現不同 的反應可能與未結合型荷爾蒙受器的濃度有關。 |
英文摘要 | Background. Uterine myomas are benign tumors of the uterus, occurring in up to 25 % of women of reproductive age. We examined the possible causes for different degrees of volume reduction in patients with uterine myomas who received gonadotropin-releasing hormone agonist (GnRHa) treatment by investigating the hormone receptors at the end of GnRHa treatment. Methods. This trial was designed as a prospective study of five premenopausal women presenting with symptomatic uterine myoma. All patients were treated with a subcutaneous injection of goserelin depot 3.6 mg every four weeks for 16 weeks. Clinical examinations, hormonal evaluation and ultrasound determinations were performed before, during and after treatment. At the end of the treatment period, all patients underwent myomectomy. The concentrations of the unbound progesterone receptors and estrogen receptors were evaluated. Results. The volume of the uterine myoma decreased by 21 % to 65 %. The percentage of decrease in volume of treated uterine myomas was found to negatively correlate with the concentration of unbound progesterone receptors (r□ = 0.92, p = 0.008). This percentage was not significantly correlated with the concentration of unbound estrogen receptors (r□ = 0.02, p = 0.84). Conclusions. The limited data available suggested that the volume decrease of uterine myomas in GnRHa-treated patients is partly dependent on the concentrations of unbound sex-hormone receptors in the uterine myomas. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。